Roivant reports Q4 GAAP EPS $0.28 on Moderna settlement; IMVT-1402 D2T RA ACR20 72.7%

Roivant Sciences Ltd.

Q4 GAAP income from continuing ops $355.7M ($0.28 diluted EPS) vs loss of $252.4M ($0.29 loss) YoY; includes $770M gain on Moderna settlement.
Non-GAAP loss from continuing ops $222.7M in Q4 vs $154.4M loss YoY; FY loss $747.7M vs $623.9M.
IMVT-1402 in D2T RA: Week 16 ACR20 72.7%, ACR50 54.5%, ACR70 35.8% in open-label period; 170 patients enrolled.
Brepocitinib NDA for DM accepted with Priority Review; launch by end Sep 2026. Breakthrough Therapy for cutaneous sarcoidosis.
Moderna settlement: $2.25B global; $950M due July 2026; additional $1.3B contingent on appeal resolution.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2026.

Period: fourth quarter and fiscal year ended March 31, 2026
Result: reported results

Exact text from the filing

On May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001635088-26-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.